Synthesis and evaluation of bivalent, peptidomimetic antagonists of the αvβ3 integrins

Feng Li, Gouri S. Jas, Guoting Qin, King Li, Zheng Li

Research output: Contribution to journalArticlepeer-review

10 Scopus citations


Targeting the integrin αvβ3 by directly interfering with its function is considered to be an effective and non-cytotoxic strategy for the treatment of tumor. In this study, a series of bivalent analogs of peptidomimetic integrin antagonists IA 1 and IAC 2 were designed, synthesized, and evaluated for their ability to inhibit the integrin αvβ3. All the bivalent ligands exhibited increased potency compared to that of their monomeric counterparts for the integrin αvβ3 with low nanomolar range binding affinity. The best bivalent ligand 6 tested in the series has an IC50 = 0.09 nM evaluated by ELISA assay. We conclude that multivalency is providing a useful template for the development novel integrin αvβ 3 antagonists as potential therapeutics.

Original languageEnglish (US)
Pages (from-to)6577-6580
Number of pages4
JournalBioorganic and Medicinal Chemistry Letters
Issue number22
StatePublished - Nov 15 2010


  • Computer modeling
  • Integrin antagonists
  • Multivalency

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Drug Discovery
  • Organic Chemistry
  • Molecular Medicine
  • Molecular Biology
  • Clinical Biochemistry
  • Biochemistry


Dive into the research topics of 'Synthesis and evaluation of bivalent, peptidomimetic antagonists of the αvβ3 integrins'. Together they form a unique fingerprint.

Cite this